Zane Abraham

Zane Abraham asked about the progress of Dupixent's rollout in CSU and COPD, including biologic penetration rates and competitive landscape against Rhapsido and Nucala. Additionally, he inquired about the 2026 vaccines guidance, specifically for Beyfortus's growth dynamics in the U.S. versus ex-U.S. markets.

Answer

Paul Hudson, CEO, and Brian Foard, EVP and Head of Specialty Care, highlighted Dupixent's strong 2025 performance, driven by volume growth across existing and new indications like COPD and CSU. They noted low biologic penetration rates in AD and CSU, suggesting market growth with new competitors. Thomas Triomphe, EVP of Vaccines, expressed satisfaction with Beyfortus's 2025 growth, attributing it to geographic expansion. For 2026, he noted potential U.S. confusion from recent pediatric immunization schedule changes but emphasized unchanged recommendations and coverage, while expecting continued ex-U.S. expansion.

Zane Abraham inquired about the progress of Dupixent's rollout in CSU and COPD, including biologic penetration, competitive landscape against Rhapsido and Nucala, and the 2026 growth assumptions for Beyfortus, differentiating between US and ex-US markets.

Answer

Brian Foard, EVP and Head of Specialty Care, highlighted Dupixent's strong 2025 performance, driven by volume growth and new indications like COPD and CSU, noting low market penetration rates. Thomas Triomphe, EVP of Vaccines, expressed satisfaction with Beyfortus's 2025 growth and discussed differing dynamics for 2026 in the US (potential confusion from new pediatric immunization schedule) and ex-US (geographic expansion), referencing a recent JAMA publication.